# GF Group Holding

> GF Group Holding is a VC fund backing Biotechnology, Industrial and Health Care. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 5
- Last investment: May 2024
- Lead investor: 0%
- Last updated: Aug 2026

GF Group Holding is a VC fund focused on Biotechnology and Industrial. GF Group Holding engages in the fields of private equity, real estate and management manage asset operates.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 40% |
| Industrial | 1 | 20% |
| Health Care | 1 | 20% |
| Collaboration | 1 | 20% |
| Manufacturing | 1 | 20% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 20% |
| Series B | 1 | 20% |
| Series C | 1 | 20% |
| Post-IPO Equity | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Switzerland | 2 | 40% |
| China | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Memo Therapeutics | Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations. | $22M | Series C | May 07, 2024 |  |
| Memo Therapeutics | Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations. | $27.6M | Series C | Nov 02, 2023 |  |
| Memo Therapeutics | Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations. | $24.9M | Series B | Feb 16, 2022 |  |
| Jcet | JCET Group manufactures semiconductor products. | $777.3M | Post-IPO Equity | May 07, 2021 |  |
| Oncobit | Oncobit enabling personalized cancer care by developing precise and highly sensitive diagnostic and monitoring tests. | $2.5M | Seed | Apr 30, 2021 |  |

5 of 5 investments shown.

## Co-investors
- [Swisscanto Private Equity](https://shizune.co/investors/profile/swisscanto-invest) — VC Fund, 4 deals together
- [Vesalius Biocapital Partners](https://shizune.co/investors/profile/vesalius-biocapital-partners) — VC Fund, 4 deals together
- [Fresenius Medical Care](https://shizune.co/investors/profile/fresenius-medical-care) — VC Fund, 3 deals together
- [Verve Ventures](https://shizune.co/investors/profile/verve-ventures) — VC Fund, 3 deals together
- [Adjuvant Capital](https://shizune.co/investors/profile/adjuvant-capital) — VC Fund, 2 deals together
- [Pureos Bioventures](https://shizune.co/investors/profile/pureos-bioventures) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does GF Group Holding invest in?

GF Group Holding invests primarily in Biotechnology, Industrial and Health Care startups, most often at Seed and Series B stage. Most of the 5 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did GF Group Holding last invest?

The most recent investment recorded for GF Group Holding closed in May 2024. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co